Kazia Therapeutics Ltd ADR
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a KZIA research report →
About the company
Kazia Therapeutics Limited, together with its subsidiaries, operates as an oncology-focused biotechnology company in Israel. The company's lead development candidate is paxalisib, a small molecule, brain-penetrant inhibitor of the phosphoinositide-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, which is in Phase II/III clinical trial for the treatment of glioblastoma; in Phase II trial to treat isocitrate dehydrogenase-mutant glioma, primary central nervous system (CNS) lymphoma, diffuse intrinsic pontine glioma, and brain metastases; and in pre-clinical studies to treat triple-negative breast cancer, as well as for the treatment of atypical rhabdoid/teratoid tumors. It also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3 that is in Phase I clinical trial to treat advanced solid tumors and ovarian cancer.
- CEO
- John Friend
- IPO
- 1999
- Employees
- 6
- HQ
- Sydney, NSW, AU
Price Chart
- Market Cap
- $21.46M
- P/E
- -1.84
- P/S
- 1568.34
- P/B
- 1.28
- EV/EBITDA
- 2.11
- Div Yield
- 0.00%
- Gross Margin
- 100.00%
- Op Margin
- -92086.45%
- Net Margin
- -113004.58%
- ROE
- -116.86%
- ROIC
- -36.21%
- Revenue
- $42.00K · -98.18%
- Net Income
- $-20,702,000 · 22.69%
- EPS
- $-18.90 · 65.64%
- Op Income
- $-14,217,000
- FCF YoY
- -38.59%
- 52W High
- $17.40
- 52W Low
- $4.86
- 50D MA
- $13.04
- 200D MA
- $9.18
- Beta
- 2.15
- Avg Volume
- 226.65K
Get TickerSpark's AI analysis on KZIA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 19, 26 | Levine James E. | other | 200,000 |
| Jun 19, 26 | Rao Sudha | other | 250,000 |
| Jun 1, 26 | Levine James E. | other | 0 |
| Mar 18, 26 | Davidson Ebru | other | 2,000 |
| Mar 18, 26 | Davidson Ebru | other | 75,000 |
| Apr 13, 26 | Rao Sudha | other | 0 |
| Mar 18, 26 | Friend John E. II | other | 30,000 |
| Mar 18, 26 | Cain David | other | 5,000 |
| Mar 18, 26 | Cain David | other | 100,000 |
| Mar 18, 26 | Cain David | other | 100,000 |
Our KZIA coverage
Recent articles, reports, and earnings notes.
No research on KZIA yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate KZIA report →Similar companies
Peers in the same neighborhood.